BioTransplant preclinical data

As assayed in cell lines, the company reported that its antibody directed against the CD2 receptor on T cells inhibits rejection by generating specific hyporesponsiveness to transplant antigens, and decreases the number of immune cells.

On rechallenge after removal of the antibody, the immune cells remained hyporesponsive to the transplant antigens. In contrast, the immune cells responded normally to other antigens. ...